Yuh Chin Huang, MD
Critical Care Medicine · Durham, NCNPI 1184737090
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Vyaire Medical, Inc. at 44.9% of the total. Reporting peaked in 2022 at $9,578 and has fallen 97.2% since, to $271 in 2025. Among critical care medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $820.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vyaire Medical, Inc.$7K
- Boehringer Ingelheim$6K
- CSL Behring$2K
- United Therapeutics Corporation$143
- Genentech USA, Inc.$125
- Polarean, Inc.$77
Across 107 payments — averaging $8598.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$634K
- AstraZeneca$145K
- United Therapeutics Corporation$82K
- Chiesi USA, Inc.$59K
What the payments were for
- Consulting fees$7,23344%
- Speaking & faculty fees$7,85748%
- Travel & lodging$8105%
- Food & beverage$4703%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vyaire Medical, Inc. | 7 | $7,373 |
| Boehringer Ingelheim | 3 | $6,398 |
| CSL Behring | 3 | $2,297 |
| United Therapeutics Corporation | 5 | $143 |
| Genentech USA, Inc. | 1 | $125 |
| Polarean, Inc. | 1 | $77 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STIOLTO RESPIMAT$6,273
- Zemaira$2,254
- Esbriet$125
- XOLAIR$125
- Pulmozyme$125
How this compares
$16,413 in reported general payments places this provider in the 90th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 502 | $414,507 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $142,153 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $78,448 |
| Dupixent SyringeDupilumab | 12 | $50,768 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $43,155 |
| Spiriva RespimatTiotropium Bromide | 38 | $29,081 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $23,445 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $20,191 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $16,962 |
| DuleraMometasone/Formoterol | 28 | $11,690 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $9,614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 294 | $9,077 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $8,232 |
| Azithromycin | 476 | $8,043 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $4,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $6,398 | $52,52778 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Durham
- Neil MacintyreDurham$70K
- Kamrooz GhadimiDurham$5K
- Lingye ChenDurham$3K
- Marija SullivanDurham$2K
- Cherylee ChangDurham$827
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.